Advanced

Mucosal output of eotaxin in allergic rhinitis and its attenuation by topical glucocorticosteroid treatment

Greiff, Lennart LU ; Petersen, H; Mattsson, E; Andersson, M; Erjefält, Jonas LU ; Linden, M; Svensson, C and Persson, C G (2001) In Clinical and Experimental Allergy 31(8). p.1321-1327
Abstract
BACKGROUND: Eotaxin is a chemokine that attracts and activates eosinophils. The present study examines the occurrence of eotaxin in nasal mucosal surface liquids in patients with seasonal allergic rhinitis without allergen exposure and during repeat allergen challenge with and without topical glucocorticosteroid treatment. The number of subepithelial eosinophils and mucosal outputs of bulk plasma (alpha2-macroglobulin) and eosinophil cationic protein (ECP) are also examined. METHODS: Twelve patients underwent daily allergen challenges for 6 days. Separately, 14 patients, who were receiving budesonide and placebo in a parallel group design, also underwent allergen challenge for 6 days. Nasal biopsies were obtained before and 24 h after the... (More)
BACKGROUND: Eotaxin is a chemokine that attracts and activates eosinophils. The present study examines the occurrence of eotaxin in nasal mucosal surface liquids in patients with seasonal allergic rhinitis without allergen exposure and during repeat allergen challenge with and without topical glucocorticosteroid treatment. The number of subepithelial eosinophils and mucosal outputs of bulk plasma (alpha2-macroglobulin) and eosinophil cationic protein (ECP) are also examined. METHODS: Twelve patients underwent daily allergen challenges for 6 days. Separately, 14 patients, who were receiving budesonide and placebo in a parallel group design, also underwent allergen challenge for 6 days. Nasal biopsies were obtained before and 24 h after the allergen challenge series, and lavages were carried out before and 15 min after selected allergen challenges. RESULTS: At baseline nasal lavage fluid levels of eotaxin correlated to levels of alpha2-macroglobulin and ECP. After the first allergen challenge there was a correlation between nasal lavage fluid levels of eotaxin and ECP. Repeat allergen exposure increased the mucosal output of eotaxin (P <0.05) and ECP (P <0.01) as well as eosinophil numbers (P <0.01), but no correlation was found between increased eosinophil numbers and eotaxin. Budesonide reduced eotaxin levels during repeat allergen challenge (P <0.05). CONCLUSIONS: Repeat allergen exposure in allergic rhinitis is associated with increased mucosal output of eotaxin. Topical budesonide attenuates this effect, suggesting the possibility that inhibitory effects on mucosal eotaxin may contribute to anti-eosinophilic actions of topical glucocorticosteroids. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
inflammation, eosinophils, cytokines, allergy, airway
in
Clinical and Experimental Allergy
volume
31
issue
8
pages
1321 - 1327
publisher
Wiley-Blackwell
external identifiers
  • pmid:11529904
  • scopus:0035724269
ISSN
1365-2222
DOI
10.1046/j.1365-2222.2001.01029.x
language
English
LU publication?
yes
id
cc0db2f8-30cc-4045-95d9-3326fdb9bd9b (old id 1120351)
date added to LUP
2008-07-01 16:20:50
date last changed
2018-01-07 05:36:04
@article{cc0db2f8-30cc-4045-95d9-3326fdb9bd9b,
  abstract     = {BACKGROUND: Eotaxin is a chemokine that attracts and activates eosinophils. The present study examines the occurrence of eotaxin in nasal mucosal surface liquids in patients with seasonal allergic rhinitis without allergen exposure and during repeat allergen challenge with and without topical glucocorticosteroid treatment. The number of subepithelial eosinophils and mucosal outputs of bulk plasma (alpha2-macroglobulin) and eosinophil cationic protein (ECP) are also examined. METHODS: Twelve patients underwent daily allergen challenges for 6 days. Separately, 14 patients, who were receiving budesonide and placebo in a parallel group design, also underwent allergen challenge for 6 days. Nasal biopsies were obtained before and 24 h after the allergen challenge series, and lavages were carried out before and 15 min after selected allergen challenges. RESULTS: At baseline nasal lavage fluid levels of eotaxin correlated to levels of alpha2-macroglobulin and ECP. After the first allergen challenge there was a correlation between nasal lavage fluid levels of eotaxin and ECP. Repeat allergen exposure increased the mucosal output of eotaxin (P &lt;0.05) and ECP (P &lt;0.01) as well as eosinophil numbers (P &lt;0.01), but no correlation was found between increased eosinophil numbers and eotaxin. Budesonide reduced eotaxin levels during repeat allergen challenge (P &lt;0.05). CONCLUSIONS: Repeat allergen exposure in allergic rhinitis is associated with increased mucosal output of eotaxin. Topical budesonide attenuates this effect, suggesting the possibility that inhibitory effects on mucosal eotaxin may contribute to anti-eosinophilic actions of topical glucocorticosteroids.},
  author       = {Greiff, Lennart and Petersen, H and Mattsson, E and Andersson, M and Erjefält, Jonas and Linden, M and Svensson, C and Persson, C G},
  issn         = {1365-2222},
  keyword      = {inflammation,eosinophils,cytokines,allergy,airway},
  language     = {eng},
  number       = {8},
  pages        = {1321--1327},
  publisher    = {Wiley-Blackwell},
  series       = {Clinical and Experimental Allergy},
  title        = {Mucosal output of eotaxin in allergic rhinitis and its attenuation by topical glucocorticosteroid treatment},
  url          = {http://dx.doi.org/10.1046/j.1365-2222.2001.01029.x},
  volume       = {31},
  year         = {2001},
}